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Background: Neuroblastoma is the most common extracranial tumors in children. At
present about the true etiology of neuroblastoma is unclear and many studies have
tried to find effective treatments for these primary malignant tumors. Although it has
been illustrated that androgen receptor (AR) was expressed in neuroblastoma cells in
some former reports, the biological role of androgen receptor in the development of
neuroblastoma is not fully understood.
Methods: Androgen (R1881) and the antagonists of androgen receptor (MDV3100 and
ARN509) were used to study the role of the androgen receptor signaling pathway in vitro
and in vivo on SH-SY5Y and Neuro-2a (N2a) cell lines.
Results: We found that AR expression showed an R1881 dose-dependent manner
in neuroblastoma cells in vitro and R1881was able to increase, while both antagonists
of androgen receptor (MDV3100 and ARN509) significantly decrease, the proliferation,
migration, invasion and sphere formation of SH-SY5Y and N2a cells. Moreover, androgen
promoted the growth of N2a tumor in vivo. However, when androgen receptor (AR) was
effectively knocked down in the two cell lines by siRNA, either promoting or inhibiting
effect of the androgen or androgen receptor antagonists, respectively, was attenuated.
Conclusion: Our results suggested that androgen receptor may involve in the
progression of neuroblastoma as well as provided insight into a new target for the
diagnosis and treatment of neuroblastoma patients.
Keywords: neuroblastoma, androgen receptor, cell proliferation, MDV3100, ARN-509
INTRODUCTION
Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for
about 8–10% of childhood cancers and for about 15% of cancer deaths in children (Ho et al.,
2016). The incidence of neuroblastoma is highest in the first year of life and the incidence rates
declines considerably thereafter and cases are rare beyond the 10th birthday. It shows aggressive
local growth and metastasizes to regional lymph nodes, liver, bone marrow, and bone cortex
(Roy Choudhury et al., 2012). Tumors in infants <1 year of age often regress spontaneously
and usually have an excellent prognosis, whereas those in older patients are aggressive, leading
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to a fatal outcome (Su et al., 2015). Despite major advances
in therapies, neuroblastoma is still associated with a high
morbidity and mortality. Thus, novel diagnostic, prognostic,
and therapeutic approaches are required, mainly to improve
treatment outcomes of high-risk neuroblastoma patients (Vella
et al., 2016).
The cause of neuroblastoma is still unclear, although previous
researches mainly focused on the hedgehog pathway, NF-κB
pathways (Chaturvedi et al., 2016), mTOR pathway (Mei et al.,
2013) and PLK1 pathways (Mao et al., 2009). However, the
role of androgen receptor ( AR) signaling pathway in molecular
pathogenesis of neuroblastoma is rarely reported.
The early studies have shown that SH-SY5Y cells expressed
AR by Northern blot analysis using a 32P-labeled probe derived
from a human AR cDNA (Yerramilli-Rao et al., 1995). Moreover,
it has been reported that androgen can induce tubulin isoforms’
upregulation in neuroblastoma cells (Butler et al., 2001). So we
speculate whether AR can regulate the growth of neuroblastoma
as it functions in prostate cancer cells.
The androgen receptor (AR) is a nuclear receptor that exerts
its effects on cells through both classical genomic mechanisms
and rapid non-genomic actions (Ciupek et al., 2015). Androgen
is mainly secreted and synthesized by testicular, adrenal glands,
and ovaries can secrete a small amount. While the most common
primary site of neuroblastoma is the retroperitoneum (adrenal
gland more often than paraspinal ganglia; Kushner, 2004). The
adrenal androgens (AAs), normally secreted by the fetal adrenal
zone, the zona fasciculata, and the zona reticularis of the adrenal
cortex are steroid hormones with weak androgenic activity. AAs
do not appear to play a major role in the fully androgenized adult
man, whereas they seem to play a role in the adult woman and in
both sexes before puberty (Sidiropoulou et al., 2000). In addition,
the incidence was slightly higher in males than that in females
(Spix et al., 2006; Navalkele et al., 2011).
Based on the situation that the expression and activity of AR
has not been well characterized in neuroblastoma tumor cells
and tumors, in our study, we investigated the effect of R1881 (a
synthetic AR agonist; Patel et al., 2015) and two AR antagonists,
MDV3100 and ARN-509, on cell viability, invasion, mobility
and sphere-formation in the neuroblastoma cell lines SH-SY5Y
(human neuroblastoma cell line) and Neuro-2a (mouse brain
neuroblastoma, N2a), respectively. MDV3100 and ARN509 are
two AR antagonists for the treatment of prostate cancer patients.
MDV3100 (Enzalutamide, brand name Xtandi), it is a novel
oral anti-androgen (Chandrasekar et al., 2015) approved by FDA
in 2012 (Schweizer and Yu, 2015). ARN509 is another second
generation of androgen receptor antagonists and mainly used in
the treatment of castration resistant prostate cancer (Wang et al.,
2016). The preliminary clinical results confirmed its security.
MATERIALS AND METHODS
Cell Culture and Treatments
SH-SY5Y, N2a, HeLa, and RAW264.7 were cultured and
maintained in Dubelcco’s Modified Eagle Media (DMEM)
(Gibcol) supplemented with 10% fetal bovine serum (FBS)
and 1% Penicillin/Streptomycin (Hyclone). For treatment with
vehicle (DMSO), R1881 or ARN-509 and MDV3100, both
obtained from APExBio, TX, USA, cells were grown in phenol
red-free DMEM (Gibco) medium supplemented with 10% (or
indicated concentration, v/v) dextran-coated charcoal stripped
FBS (Biological Industries, Israel) for 72 h prior to treatment.
Cells were incubated at 37◦C in a humidified incubator
containing 5% CO2. To inhibit AR expression, siRNAs targeting
full length AR (siARa, 3′- AAGACGCUUCUACCAGCUCAC
-5′; siARb, 3′- AAGAAGGCCAGUUGUAUGGAC -5′; siARc,
3′-GACCUACCGAGGAGCUUU-5′) or siRNA control ordered
from GenePharma (Shanghai, China) were transfected using
Lipo2000 transfection reagent (Invitrogen) in accordance with
the manufacture’s protocol.
Western Blots
Cell lysis, protein extraction, and immunoblotting were
performed as described previously (Wang et al., 2011).
MTT/Cell Viability Assay
The proliferative effects of R1881 and the anti-proliferative effects
of MDV3100 and ARN509 were measured in vitro by using MTT
assay. Briefly, the cells were seeded into 96-well plates at a density
of 4,000 cells/well. After treatment, the medium was replaced
with fresh culture medium contained 0.5 mg/ml MTT reagent
and incubated at 37◦C for 4 h. Subsequently, the supernatant was
aspirated, and cells were lysed in 200 µl DMSO for 10 min at
37◦C. The optical density (OD) was measured at 490 and 570 nm
using a plate reader. Each experiment was performed in triplicate.
Immunofluorescence
SH-SY5Y and N2a cells were fixed with 4% paraformaldehyde in
1X PBS at 4◦C for 30 min. The slides were incubated with rabbit
anti-AR antibody (Santa Cruz) for 1 h, followed by 1 h incubation
of TRITC anti-rabbit IgG antibody (Thermo) and stained with
DAPI (for the nucleus). Samples were mounted using anti-fade
mounting medium, and then visualized with a fluorescent light
microscope.
Wound Healing Assay
SH-SY5Y and N2a cells were cultured in six-well plates
(5× 105cells/well) and incubated until they reached 90–100%
confluence. SH-SY5Y and N2a cells were then maintained in
phenol red-free DMEM with 2.5% cFBS (charcoal stripped
FBS) or 5% cFBS, respectively, in order to minimize the cell
proliferation. A sterile 20µl tip was used to create scratch wounds
of the same width on each monolayer. The plates were then
washed twice with phosphate-buffered saline (PBS) to remove
the detached cells. Photos were taken at 0, 24, and 48 h, and
the distance traveled by the cells enumerated the closure of the
wounds. Each experiment was performed in triplicate.
Trans-Well Invasion Assay
The cells were seeded in the top chamber of MatrigelTM-coated
inserts (pore size: 8 µm; Falcon) placed in 24-well plates (2
× 104cells/well for SH-SY5Y), while a medium supplemented
with 10% cFBS (charcoal stripped FBS) was used as a chemo-
attractant in the lower chamber. The wells were coated with
100 µl of MatrigelTM (BD Bioscience) at a dilution of 1:40
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(Matrigel: serum-free medium) and air-dried overnight in a
biosafety cabinet. The cells were allowed to invade through the
MatrigelTM for 48 h at 37◦C in a 5% CO2 incubator. Cells that did
not invade were scraped off with a cotton-tip applicator while
the invading cells were fixed and stained with 0.005% crystal
violet. The number of invading cells was counted under a light
microscope (x10 objective) from three fields for each well. Each
experiment was performed in triplicate.
3D Culture and Sphere-Formation Assay
Single N2a cell suspension was suspended in MatrigelTM/serum
free DMEM (1:1) at a concentration of 2 × 103cells/well or 4 ×
103 in a total volume of 50µl. The solution was then plated gently
individual wells of a 96-well plate and allowed to solidify for 1
h at 37◦C. One-hundred microliter of phenol red-free DMEM
with 5% cFBS was added gently to the each well and the media
(containing the treatment) was changed every 2–3 days. The
numbers and morphology of colonies were then counted and
observe under a microscope. Each experiment was performed in
triplicate.
Soft Agar Colony Forming Experiment
Warm (37◦C, 500 µL per well) base agar solution (1.5% agar) in
1 × DMEM complete culture media) was poured into each well
of 24-well plate. The base layer was allowed to solidify at 4◦C
for 30 min. Then 500 µL of a warm (37◦C) top agar solution
consisting of 8,000 SH-SY5Ycells in 0.7% agar + 1 × DMEM
complete tissue culture media was added over the base layer. The
24-well plates were then incubated at 37◦C in the humidified
incubator for 3 weeks; 500 µL of fresh media was added every 3
days without disturbing the cells. After 3 weeks, the colonies were
stained with 0.005% crystal violet. The numbers and morphology
of colonies were then counted and observe under a microscope.
Each experiment was performed in triplicate.
Animal Xenograft Models
To evaluate the efficacy of androgen promoting neuroblastoma
cells growing in vivo, 106 N2a cells in 10 µl of PBS were injected
into the exposed adrenal glands of immunocompromised mice.
Five days prior to N2a cells inoculation, 10 out of 15 of the
male mice were castrated to eliminate the androgen impact
of the testes. Meanwhile 5 intact male mice were of sham
surgery. Fifteen male and 12 intact female 4-week-old mice were
anesthetized, the left flanks were prepared in sterile fashion, and
transverse incisions were performed to expose the left kidneys
and the adrenal glands. The mice were then intraperitoneally
injected with testosterone propionate (TP, 0.5 mg/kg body
weight) dissolved in sesame oil (vehicle) or merely the vehicle.
Thus, all the mice were divided into 5 groups: castrated male
TP group (n = 5), intact male vehicle group (n = 5), castrated
male vehicle group (n = 5), intact female TP group (n = 6)
and intact female vehicle group (n = 6). Each group was treated
every 3 days for 2 weeks and then sacrificed. To evaluate the
effect of androgen on the survival time of N2a bearing mice, 13
castrated male mice were injected with 2 × 106 N2a cells into
the adrenal glands. One week after the inoculation, the mice were
randomly separated into two groups and then injected every 3
days intraperitoneally with testosterone propionate (n= 6) or the
vehicle (n = 7), respectively. The cumulative survival curve was
generated by SPSS 17.0.
Ethics Approval
All mice experiments were carried out with ethical committee
approval and met the standards required by the Dalian Medical
University Animal Care and Use Committee guidelines.
Data Analysis
Statistical analysis was performed using GraphPad Prism version
5. The significance of the data was analyzed using a Student’s t-
test, and p-values of p< 0.05 (∗), p< 0.01 (∗∗) and p< 0.001 (∗∗∗)
were considered significant and highly significant, respectively.
RESULTS
AR Expression in SH-SY5Y and Neuro-2a
Cells was R1881-Dose-Dependent
To determine the expression level of AR protein in
neuroblastoma and other cell lines, neuroblastoma cell lines
(SH-SY5Y and N2a), human cervical cancer cell line HeLa and
mouse leukaemic monocyte macrophage cell line Raw264.7 were
analyzed with Western blotting assay. Neuroblastoma cell lines
exhibited high level of AR expression while no AR expression
was detected in HeLa or Raw264.7 cells (Figure 1A). Western
blotting result also showed that siRNA(a) targeting full length
AR significantly reduced the AR expression in SH-SY5Y and N2a
cells (the siARa target sequences are similar in both human and
mouse, Figures 1B,C). Thus, siARa was applied for knockdown
of AR in the following experiments.
Androgen-induced AR expression was also analyzed. AR
expression and proliferative effect of R1881, a synthetic androgen
as the AR agonist, in both cell lines were in a dose-dependent
manner (Figures 1D,E). Furthermore, translocation of AR from
cytoplasm to nucleus upon ligand-binding can be reduced by
AR antagonist (Figure 1F). Intriguingly, with vehicle treatment,
AR expressed in both the cytoplasm and nucleus suggesting the
constitutive AR activity in neuroblastoma cells.
R1881 Promotes and AR Antagonists
Inhibit the Cell Proliferation of
Neuroblastoma in vitro
We first studied the in vitro effect of AR signaling on the cell
proliferation of SH-SY5Y and N2A cells lines via MTT assays.
The neuroblastoma cells were treated with R1881 (10 nM), a
synthetic agonist of AR, or the antagonists of AR, ARN509 (10
µm), and MDV3100 (10 µm) for 72 h. The results showed that
R1881 promoted the proliferation of SH-SY5Y and N2a, while
the antagonists of AR dramatically inhibit the proliferation of
the two cell lines (Figures 2A,B). On the other hand, there was
no significant difference of the proliferative activity when AR
knockdown cells treated with AR agonist or antagonists in the
two neuroblastoma cell lines (Figures 2C,D). Besides, inhibition
of AR expression with siRNA led to decreased cell proliferation
in both cell lines.
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FIGURE 1 | AR expression in SH-SY5Y and Neuro-2a cells was in a R1881 dose-dependent manner. (A) Neuroblastoma cells (SH-SY5Y and N2a), human
cervical cancer cell line HeLa and mouse leukaemic monocyte macrophage cell line Raw264.7 were lysed and AR was determined by western blot assay (30 µg total
protein per lane). All the cell lines werecultured in DMEM supplied with 10% FBS. (B,C) Neuroblastoma tumor cells (SH-SY5Y and N2a) were transfected with AR
siRNAs (siARa, siARb, siARc), after 72 h cells were lysed and AR was determined by western blot assay. Actin served as internal control. (D,E) AR expression and cell
viability induced by R1881 were in a dose-dependent manner. (D) Cells were treated with DMSO or 1 nM or 10 nM R1881 for 72 h. Actin served as internal control.
(E) R1881-dose-dependent cell viability was determined using MTT assay. Results are expressed as a percentage of the treated group compared to its control. Data
represent an average of three independent experiments. The data are reported as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001). (F) R1881 enhanced and AR
antagonists impaired AR nuclear-localization. Representative fluorescent microscopic images of SH-SY5Y and N2a cultured (cFBS) and treated with DMSO (vehicle),
R1881 (10 nM), MDV3100 (10 µM) combined with R1881 (10 nM), or ARN509 (10 µM) combined with R1881 (10 nM) for 1 h. Scale bar = 10 µm.
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FIGURE 2 | The effects of androgen (R1881) and the antagonists of AR (ARN509 and MDV3100) on the proliferation of SH-SY5Y and N2a cells. (A,B)
After incubation of the two cell lines (SH-SY5Y and N2a) for 0, 24, 48, and 72 h with R1881 (10 nM) or MDV3100 (10 µM) or ARN509 (10 µM), cell proliferation was
determined using MTT assay. Results are expressed as the optical density of the wells on a 96-well dish. (C,D) 72 h after siRNA transfection, the same treatment was
performed as above. Data represent an average of three independent experiments. The data are reported as mean ± SD (** P < 0.01, *** P < 0.001).
Vehicle (DMSO)-treated cells grew well, but slow, that
suggests AR activity is important but not the unique factor to
neuroblastoma cells’ growth. Besides, it suggested neuroblastoma
cells produce hormones to induce the growth of their own, which
explained the nuclear expression of AR with vehicle treatment
(Figure 1F) as well as administration of AR antagonists can
achieve better growth inhibition compared with the vehicle
(Figures 2A,B).
R1881 Promotes and AR Antagonists
Inhibit the Migratory Ability of
Neuroblastoma Cell Lines
A wound-healing assay was used to evaluate the effect of R1881
and the AR antagonists, ARN509, and MDV3100, on migration
of both cell lines. R1881 obviously promoted cell migration
and the cells were able to almost close the wound at 48 h,
while both ARN509 and MDV3100 significantly inhibited the
migration of the treated cells (Figures 3A,B). However, the
migratory ability of neuroblastoma cells was largely reduced by
siARa (Figure 3A vs. Figure 3C and Figure 3B vs. Figure 3D, in
vehicle and R1881-treated groups). The result also demonstrated
that AR knockdown attenuated the agonist effect of R1881 and
the antagonist effect of MDV3100 and ARN509 (Figures 3C,D).
These showed R1881 promote the migratory ability of both
neuroblastoma cell lines while AR knockdown, ARN509 and
MDV3100 suppress the migratory ability.
Androgen Promotes and AR Antagonists
Inhibit the Invasive Ability of SH-SY5Y Cells
Next, we use MatrigelTM-coated trans-well experiments to detect
cell invasion. R1881 obviously increased the amount of invasive
cells compared with DMSO or AR antagonists treatment
(Figures 4A upper panel, B). Interestingly, depletion of AR by
siRNA attenuated the effect of either R1881 or AR antagonist
(Figures 4A lower panel, B). These results indicated that the
invasive abilities of SH-SY5Y cell line were closely related to AR
signaling activation. The assay was not performed on N2a cells
since they failed to show an ability to invade when using FBS as a
chemo-attractant.
Androgen Promotes Cell Sphere Formation
of Neuroblastoma Cells While Antagonist
of Androgen Receptor Inhibits Cell Sphere
Formation
In order to better visualize the sphere-forming capabilities of
neuroblastoma cells, single cell suspensions of SH-SY5Y and
N2a were cultured in soft agar and MatrigelTM for 21 and
7 days, respectively. The spheres were then visualized under
an inverted light microscope and bright field images were
acquired. Both cell lines treated with R1881 produced more and
relatively larger spheres, while cells treated with AR antagonists
produced significantly smaller spheres, compared to those cells
treated with vehicle (Figures 5A,C, upper panles). Inhibition of
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FIGURE 3 | The effects of androgen (R1881) and the antagonists of AR (ARN509 and MDV3100) on the migration ability of SH-SY5Y and N2a cells. (A,B)
A scratch was made in a six-well plate of confluent SH-SY5Y and N2a cells using a 200 µl tip, images were taken at T = 0, 24, and 48 h with indicated treatment,
and quantification of the distance of the wound closure was assessed over time using Image-Pro Plus 6.0. (C,D) 72 h after siRNA transfection, the same treatment
was performed as above. Results are expressed as the pixels between the two lines. Data represent an average of three independent experiments. The data are
reported as mean ± SD (***P < 0.001).
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FIGURE 4 | The effects of androgen (R1881) and the antagonists of AR (ARN509 and MDV3100) on the invasion of SH-SY5Y cells. (A,B) SH-SY5Y cells
were seeded onto the MatrigelTM-coated membrane in the top chamber of the trans-well with indicated treatment in the presence of 5% cFBS in the lower chamber.
Cells that invaded to the lower chamber after 48 h were fixed with paraformaldehyde, stained with 0.005% crystal violet, counted and represented as a number of
invaded cells. Scale bar = 100 µm. 72 h after siRNA transfection, the same treatment was performed as above. Data represent an average of three independent
experiments. The data are reported as mean ± SD (*P < 0.01, **P < 0.01, ***P < 0.001).
AR expression by siRNA obviously blocked the promoting or
suppressing effect of R1881 or AR antagonists, respectively on
sphere formation of both cell lines (Figures 5B,D).
Androgen Promotes Neuroblastoma
Xenograft Tumor Growth
To further evaluate the efficacy of androgen on cancer cells
growth in vivo, N2a neuroblastoma cells were injected into the
adrenal glands of nude mice, and mice were treated with either
vehicle alone or testosterone propionate dissolved in the vehicle.
Testosterone propionate treatment resulted in increased tumor
volume in both male and female mice (Figures 6A,B) as well
as shorter survival time in male mice (Figure 6C). These results
indicated the proliferative effect of androgen in N2a xenograft
models.
DISCUSSION
The present study indicated that AR agonist R1881 obviously
promoted cell proliferation, migration, invasion and sphere
formation of both neuroblastoma cell lines, SH-SY5Y and N2a,
in vitro and the progression of N2a in vivo. While the antagonists
of AR, MDV3100 and ARN509, played an opposite role in vitro.
Moreover, the promoting and suppressing effects of AR agonist
and antagonists, respectively, had been evidently attenuated
by inhibition of endogenous AR expression, suggesting that
AR signaling pathway may take part in the progression of
neuroblastoma. However, the underlying mechanism is still
uncertain and will be illustrated in our future studies. The two
AR antagonists in the treatment of prostate cancer have achieved
good clinical curative efficacy, therefore they are expected to
become the new drugs for the treatment of neuroblastoma in the
preclinical study.
Androgen and androgen receptor (AR) signaling has an
important role in the initiation and progression of many
hormone-related cancers including prostate and breast cancer
(Chang et al., 2014). AR is primarily responsible for mediating
the physiological effects of androgens by binding to specific DNA
sequences, androgen responsive element (ARE), which is present
in regulatory elements on the AR-responsive target genes, such
as vascular endothelial growth factor (VEGF) (Bolton et al.,
2007), matrix metalloproteinases (MMPs) (Joshi et al., 2007), and
tubulin (Mariani et al., 2015).
First of all, it’s well accepted that cell proliferation and
migration are mainly regulated by receptor tyrosine kinase
ligands such as, a major contributor to angiogenesis, VEGF
(Roy Choudhury et al., 2012). Previous studies have shown that
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FIGURE 5 | The effects of androgen (R1881) and the antagonists of AR (ARN509 and MDV3100) on the sphere-forming ability of SH-SY5Y and N2a
cells. (A,B) Representative bright-field images of SH-SY5Y spheres with indicated treatment. Images were visualized by inverted microscope at 10x magnification.
Scale bar = 50 µm. According to the size, the spheres are divided into three groups and their diameters were auto-calculated by Image-Pro Plus 6.0. Data represent
an average of three independent experiments. (C,D) N2a spheres, 72h after siRNA transfection, the same treatment was performed as above. Scale bar = 100 µm.
The data are reported as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001).
VEGF and its receptors are expressed in human neuroblastoma
tumors and cell lines, and several experimental therapeutic
strategies have been emerged to target the interaction of VEGF
with its receptors and thereby to suppress the growth of
neuroblastoma (Ribatti and Ponzoni, 2005). More than that,
the AR binding sites were discovered in the VEGF promoter
and in vivo binding of AR to these sites was demonstrated
by chromatin immunoprecipitation (Eisermann et al., 2013).
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FIGURE 6 | Testosterone propionate promoted N2a tumor growth in vivo. Mice bearing adrenal N2a xenograft tumors were treated with testosterone
propionate or vehicle and the tumors were harvested together with the kidneys at the end of the experiment. (A,B) Representative pictures of harvested tumors are
shown in groups. The kidneys were placed below the dashed lines. (C) Cumulative survival among N2a bearing castrated male mice treated with testosterone
propionate (n = 6) or vehicle (n = 7).
Concerning that VEGF, an angiogenesis stimulator, has been
detected in neuroblastoma tumors (Amoroso et al., 2015), we
inspected the necrosis areas on N2a xenograft tumor (shown in
Figure 6A) sections which may be consequences of inadequate
blood supply. Unsurprisingly, testosterone propionate treated
tumors exhibited less necrosis areas compared with vehicle
treated tumors (Supplemental Figure 1A) in both male and
female mice groups (Supplemental Figure 1B), suggesting an
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angiogenesis potential of AR signaling. Therefore, we speculate
that activation of AR signaling induces VEGF production so as to
promote proliferation and migration of the neuroblastoma cells.
On the other hand, it has been reported that the
naturally occurring endogenous angiogenesis inhibitors affect
neuroblastoma growth in vivo, especially the tissue inhibitors
of matrix metalloproteinases (MMPs) (Joshi et al., 2007). In
addition, MMPs express in human neuroblastoma and in
advanced stages of neuroblastoma, and tumor cells secret MMPs
favoring degradation of extracellular matrix and enhancing
tumor dissemination (Roy Choudhury et al., 2012). Thus, MMPs
facilitate invasion and migration of cancer cells. Furthermore,
it has been confirmed that androgen response elements (AREs)
involved in androgen-induced MMP-2 expression and MMP-2
expression is blocked by the androgen antagonist bicalutamide
at the mRNA level (Li et al., 2007). Besides, MMP-2, MMP-9
and MMP-7 expression were confirmed in the SH-SY5Y cells
(Lu et al., 2009). MMP9 is also a downstream target gene of AR
(Li et al., 2015). So, in the present study, MMPs may contribute
to the invasion ability of SH-SY5Y. Nevertheless, expression of
endogenous MMP-2, MMP-9, and TIMP-1 (tissue inhibitor of
matrix metalloproteinase 1) was not detected or at times barely
detectable in the non-differentiated and differentiated N2a cells
(Sbai et al., 2008). All above explains the difference of the invasive
ability between SH-SY5Y and N2a. Thus, we propose another
mechanism that AR signaling increases MMPs expression and
consequently promotes invasion of neuroblastoma cells.
Furthermore, a major protein up-regulated in response to
androgens in regenerating motor neurones is tubulin, the
structural component of microtubules (Matsumoto et al., 1993).
Previous experiments have confirmed that testosterone treatment
of proliferating SH-SY5Y cells resulted in an increase in the
level of the two tubulin subunits alpha- and beta-tubulin, and
anti-androgens counteract the effect of testosterone on tubulin
(Butler et al., 2001). Moreover, Tubb3, a beta-tubulin isotype,
was found a direct target of AR and the AREs was determined
(De Gendt et al., 2011) Beyond that, the protein interaction of
AR with tubulin was reported facilitating nuclear translocation
of AR (Zhu et al., 2010). Thus, we can reasonably infer
activated AR signaling may induce tubulin expression leading to
neuroblastoma growth.
In conclusion, we have demonstrated that the androgen
effectively promotes the progression of neuroblastoma tumor
cells. More important, our result indicates the anti-tumor role of
MDV3100 and ARN509 on neuroblastoma cells by targeting AR
as well as provides insight into the anti-androgen treatment of
neuroblastoma.
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Supplemental Figure 1 | Testosterone propionate decreased the necrosis
of N2a tumor in vivo. (A) Sections of harvested N2a xenograft tumors from mice
treated with vehicle and testosterone propionate were
formalin-fixed-paraffin-embedded and stained with hematoxylin and eosin (HE). N,
necrosis area. Scale bar = 100µm (B) The areas occupied by necrosis on
indicated sections were statistically calculated using Image Pro-Plus 6.0. 5
pictures of views were taken randomly on an HE stained section, tumor sections
from 3 mice were analyzed in each group. T.P., testosterone propionate. The data
are reported as mean ± SD (∗∗∗P < 0.001).
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